Abstract. In order to be active, antisense oligonucleotides (ASOs) should be delivered to the nuclei of cells. The lack of effect of some ASOs might be explained by poor distribution inside the cell. Here we describe the study of the intracellular distribution of an ASO in a leukemic cell line in which the ASO was not showing an effect. We used fluorescein isothiocyanate-labeled ASO and fluorescent or confocal microscopy. The internalised ASO was localized in a specific intracellular juxtanuclear region, showing no cytoplasmic or nuclear diffusion. Transfection of the ASO improved cellular distribution to the cytoplasm and nuclei and improved the ASO effect.
Antisense technology aims at downregulating gene expression by targeting a specific mRNA with antisense oligonucleotides (ASOs). Once internalized by cells, ASOs hybridize to complementary mRNA sequences. This decreases gene expression either by the action of RNase H that recognizes the DNA/ mRNA hybrids and cleaves that mRNA or by formation of oligonucleotide / mRNA complexes causing ribosomal blockage (1) . However, this technology is frequently hindered by problems related to internalization of the ASOs (2) . It is known that the oligonucleotides are incorporated into the cell by endocytosis, in a concentration dependent manner: below the concentration of 1 µM predominantly via a receptor-like mechanism (3) and at higher concentrations, mainly by fluid-phase endocytosis (2) . To be most effective, the ASOs should be also delivered to the nuclei (4) and therefore several uptake improvement strategies have been developed such as the use of streptolysin O (5), chemical modifications of the oligonucleotides (6), attachment of the oligonucleotides to cholesterol (7) , or the use of nanosized cationic hydrogels (8) . Perhaps one of the most successful strategies is the use of cationic lipids, which are known to increase the oligonucleotide uptake up to 250-fold as well as its cytoplasmic bioavailability (1, 9) . However, poor uptake might not be the only availability related reason for the poor function of some ASOs. Distribution once inside the cell might be also important for ASO availability.
Previous work carried out by our group was aimed at inhibition of the transferrin receptor 1 (TfR1) expression by treating cells with ASOs (10) . While carrying out this work, it was verified that in a particular cell line, K562 (CML erythroblastic), the ASO had no effect. This observation led us to study the subcellular localization of the TfR1 ASO in the K562 cells. Here, we report that the ASO was localized in a specific intracellular region, not being distributed to the cytoplasm and nuclei. This may be the reason for its lack of function in this cell line.
The TfR1 oligonucleotides were designed using the GenEMBL database and further analyzed with the FASTA program. The sequences used were as follows: ASO: 5'-ATC TAG CTT GAT CCA TCA T-3' and (sense oligonucleotide control) SO: 5'-ATG ATG GAT CAA GCT AGA T-3'. The oligonucleotides used in the fluorescence and confocal microscopy studies were labeled with fluorescein isothiocyanate (FITC). All were phosphorothioate oligonucleotides and were purchased from Eurogentech (Seraing, Belgium). For the cellular viability studies, cells were cultured at 2 × 10 5 cells/ mL in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS) and 2 mM Lglutamine (Gibco, Paisley, UK). For these studies and the intracellular distribution studies without the help of lipofectin, cells were incubated with 20 µM FITClabeled TfR1 ASO or SO at day 1. Further additions of oligonucleotides were as follows: half the dose at 24 h and a fourth of the dose at 48 h. Cells were incubated in a humidified incubator at 37°C with 5% CO 2 in air. Cell growth and viability were assessed on days 4, 7, and 9 using the Trypan blue exclusion assay. For the transfection studies, cells were incubated at 1 × 10 6 cells / mL in OPTIMEM with glutamax (Gibco), with lipofectin (according to the manufacturer's instructions; Life Technologies, Gaithersburg, MD, USA) and with TfR1 ASO or SO at 0.5 µM for 4 h. These concentrations of oligonucleotides were considerably smaller than in the studies without the help of lipofectin, since according to the existing literature the uptake of oligonucleotides with lipofectin was much higher than without lipofectin (1, 9) . After 4 h, the cells were transferred to 6-well plates and 4 mL of RPMI 1640 supplemented with 10% heat inactivated FBS and 2 mM L-glutamine was added. Cells were analyzed at various times following incubation with the FITC-labeled oligonucleotides using an Olympus BH-2 fluorescence microscope with an appropriate FITC filter. Photographs were taken with an Olympus PM-10ADS automatic photomicrographic system and an Olympus C-35AD4 camera. For the confocal microscope (MRC600; Bio-Rad, Amadora, Portugal) analysis, cells were further treated with RNase and propidium iodide. Flow cytometric analysis of TfR1+ cells was carried out in cells treated as indicated above, with or without lipofectin, 96 h after treatment. Basically, cells were resuspended in PBS-1% FBS and incubated with FITC-conjugated anti-TfR1 antibody (JT.01 clone, 10 µl / test; Immune Source, CA, USA) or FITC-conjugated IgG2a as a control (DC.3 clone, 10 µl / test; Immune Source). After fixing the cells, analysis of the labeled population was carried out using an Epics XL-MCL Flow Cytometer (Beckman Coulter, High Wycombe, UK). Results are expressed as % decrease in SI (staining index) of ASO-treated cells in relation to SO-treated cells. SI = (mean peak sample − mean peak negative control) / autofluorescence. Therefore % SI of the ASO compared to the SO = 100 − [SI (ASO) / SI (SO)] × 100. Differences between treatments with or without lipofectin were analyzed using a paired t-test (StatView 4.02 for MacIntosh).
The effect of the ASO, delivered to K562 cells without transfection reagent, on viable cell number was investigated. A lack of specific antisense effect was observed since there was no difference between the number of viable cells between the ASO and SO treatment. Only a nonspecific cytotoxic effect was verified (Fig. 1) . When investigating the intracellular distribution of the ASO by fluorescence microscopy, under the same conditions of delivery to the cells as in the previous studies, it was verified that there was an initial staining of most of the cells at 3 h, possibly due to ASO around the cell membrane and not to its actual presence inside the cell. At 24 and 48 h the ASO mostly exhibited a dotlike appearance which probably illustrates the expected fluid-phase endocytosis process of uptake, with most fluorescence being detected in vesicles and with no significant cytoplasmatic or nuclear diffusion of the ASO (Fig. 2) . Furthermore, there was an unexpected localization of the vesicles, which appeared to be in the Golgi complex. The percentage of cells that displayed that morphology was determined with a FITC-labeled control-ASO previously designed towards the bcr-abl translocation (10) , by counting at least 250 cells per experiment in three independent experiments. The percentage ± S.E.M. determined was 68.3 ± 7.6% at 3 h, 90.9 ± 4.1% at 24 h, and 96.3 ± 3.0% at 48 h.
In order to further confirm if the ASO localization was in fact intracellular and not bound to the cellular membrane, the cells treated with the FITC-labeled TfR1-ASO were observed by confocal microscopy (Fig. 3A) . Results from single confocal slices clearly showed the intracellular presence of the ASO, which was mostly present in vesicles. The vesicle appearance was the same as that observed by fluorescence microscopy and seemed to correspond to the Golgi complex. There was very little nuclear staining. We believe that it is possible that this localization could be preventing the ASO from exerting its action.
We attempted to improve the intracellular distribution of the ASO by transfection with lipofectin. A lower concentration of ASO was used, according to the manufacturer's instructions. Fluorescence microscopy results from K562 cells transfected with lipofectincoupled FITC-ASO indicated that the oligonucleotide internalization, with the ideal oligonucleotide / lipofectin ratio (0.5 µM oligonucleotide and 15 µg / L lipofectin), promoted a diffuse staining of the cytoplasm and nucleus. There was no further evidence of oligonucleotide entrapment inside vesicles (Fig. 3B) . Curiously, whenever the oligonucleotide / lipofectin ratio was increased, the oligonucleotide uptake assumed the classic (non-transfected) vesicular pattern (data not shown).
In order to compare the antisense action of the ASO under these two different conditions of uptake and distribution, the percentage inhibition of TfR1 expression was studied by flow cytometry after treating the cells with the referred conditions: 20 µM ASO without the help of lipofectin or with 0.5 µM ASO with the help of lipofectin. Results showed that the percentage inhibition of TfR1 expression (± S.E.M.) 96 h after 20 µM ASO treatment without lipofectin, compared to the SO treatment, was only 9.3 ± 3.8% (n = 4 independent experiments). However, when transfecting a much smaller concentration of ASO (0.5 µM) with lipofectin, the reduction of TfR1 expression increased to 32.1 ± 7.6% (n = 4 independent experiments). The difference between these values was considered statistically significant (P = 0.03).
It is possible that the aggregate of vesicles was entrapping the ASO and preventing it from exerting its action. Further studies with quantification of uptake and distribution of the ASO in this cell line would be necessary to confirm this hypothesis. This is the first report of a particular localization pattern of an ASO in K562 cells. The reason for an entrapment of oligonucleotides in the K562 cell line is not known. However, the cellular distribution of a different ASO, designed towards the bcr-abl mRNA, presented the same distriution pattern in this cell line (data shown above) and we did not find this pattern of localization in other leukemic cell lines in which the TfR1-ASO had an antisense effect (data not shown). This suggests that the intracellular distribution is not dependent on the oligonucleotide sequence but is dependent on the cell line used.
Others have showed that K562 cells resistant to the cytotoxic effect of daunorubicin could sequester this drug in intracellular vesicles, where it was detectable for several days (11) . Those particular K562 cells had an unknown drug sequestration mechanism, which utilized daunorubicin compartmentalization without efflux to confer drug resistance. The cells used in the present study may activate the same sequestration mechanism for compartmentalization of ASOs, conferring resistance to these molecules. Thus, K562 cells may not have the same capacity as other cells to "spread" ASOs in the cytoplasm due to this sequestration mechanism. This may be a cell type specific effect and may be related to a cell cleansing or defense process. The subcellular localization described here may also be related to the efflux process of oligonucleotides, previously described by others (12 -15) .
